CNS Cancers

Evaluation of Insomnia

Details for evaluating insomnia and a list of the major categories of sleep disorders.

Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma

Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma

By

EGFR-amplified tumors had a high rate of response.

Glioblastoma: Temozolomide, Bevacizumab May Improve Outcomes Among Elderly Patients

Glioblastoma: Temozolomide, Bevacizumab May Improve Outcomes Among Elderly Patients

By

Researchers enrolled 66 patients with glioblastoma to evaluate the safety and efficacy of upfront temozolomide with bevacizumab.

Tumor-treating Fields Do Not Negatively Affect Health-related QoL

Tumor-treating Fields Do Not Negatively Affect Health-related QoL

By

A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.

Pediatric Patients Hospitalized for Pneumonia May Have Elevated Cancer Risk

Pediatric Patients Hospitalized for Pneumonia May Have Elevated Cancer Risk

Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.

Sorafenib Plus Temsirolimus Demonstrates Limited Benefit in Glioblastoma

Sorafenib Plus Temsirolimus Demonstrates Limited Benefit in Glioblastoma

By

Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.

Tumor Treating Fields May Improve Glioblastoma Outcomes

Tumor Treating Fields May Improve Glioblastoma Outcomes

By

TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

By

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Patients With Meningioma Have Inferior Quality of Life Post-surgery

Patients With Meningioma Have Inferior Quality of Life Post-surgery

By

Researchers reviewed data from 1722 patients diagnosed with meningioma between 2006 and 2013 to determine whether the growth itself and/or treatment reduce patient QoL.

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy

By

Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

By

First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.

Rindopepimut Not Associated With Prolonged Survival in Glioblastoma

Rindopepimut Not Associated With Prolonged Survival in Glioblastoma

By

At the preplanned interim analysis, the study was discontinued for futility.

Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype

Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype

By

Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.

FDA Grants Orphan Drug Status to SurVaxM for Glioblastoma

FDA Grants Orphan Drug Status to SurVaxM for Glioblastoma

By

The US Food and Drug Administration granted orphan drug status to SurVaxM for patients with glioblastoma.

Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma

Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma

By

Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.

Glioblastoma: pp65 Vaccine With High-dose Temozolomide May Improve Survival

Glioblastoma: pp65 Vaccine With High-dose Temozolomide May Improve Survival

By

With vaccine treatment, 4 patients had not progressed for more than 4.9 years and 3 patients had not progressed more than 7 years post-diagnosis.

Phase 3 Trial: Vaccine Trial for Patients with Glioblastoma

Phase 3 Trial: Vaccine Trial for Patients with Glioblastoma

By

Researchers are attempting to determine the clinical efficacy of ICT-107, a dendritic cell vaccine, among patients with newly diagnosed glioblastoma.

Brain Metastasis Management Varies Among Oncologists

Brain Metastasis Management Varies Among Oncologists

By

Practice patterns for the management of patients with more than 3 brain metastases appear to vary widely among radiation oncologists.

Rapid Rituximab Administration Safe for Primary CNS Lymphoma

Rapid Rituximab Administration Safe for Primary CNS Lymphoma

By

Rapid administration of rituximab over 90 minutes was safe and feasible for patients with primary central nervous system (CNS) lymphoma.

Onartuzumab Does Not Improve Clinical Outcomes in Glioblastoma

Onartuzumab Does Not Improve Clinical Outcomes in Glioblastoma

By

Onartuzumab does not improve clinical outcomes for patients with glioblastoma when given with bevacizumab.

Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma

Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma

By

Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.

Less Cognitive Deterioration With Radiosurgery Among Patients With Brain Metastases

Less Cognitive Deterioration With Radiosurgery Among Patients With Brain Metastases

By

Among patients with 1 to 3 brain metastases, use of stereotactic radiosurgery (SRS) may result in less cognitive deterioration at 3 months.

New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma

New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma

By

Two novel regimens showed significant anti-tumor activity in patients with neuroblastoma.

MATRix Regimen as New Standard for Primary CNS Lymphoma

MATRix Regimen as New Standard for Primary CNS Lymphoma

By

The MATRix regimen may be the new standard chemoimmunotherapy for the treatment of central nervous system (CNS) lymphoma.

Methotrexate, TMZ, and Rituximab Followed by hWBRT Safe for Patients With CNS Lymphoma

Methotrexate, TMZ, and Rituximab Followed by hWBRT Safe for Patients With CNS Lymphoma

By

Treatment of primary central nervous system lymphoma with methotrexate, TMZ, and rituximab, followed by hWBRT and subsequent TMZ was safe.

Rindopepimut May Help Patients With EGFRvIII-Positive Recurrent Glioblastoma

Rindopepimut May Help Patients With EGFRvIII-Positive Recurrent Glioblastoma

By

New data from a phase 2 study of rindopepimut in patients with EGFRvIII-positive recurrent GBM showed a marked benefit in terms of overall survival.

BRCA1 Gene Expression May be Biomarker for Survival in Glioblastoma Multiforme

BRCA1 Gene Expression May be Biomarker for Survival in Glioblastoma Multiforme

By

BRCA1 protein expression may be an important predictive biomarker of overall survival in glioblastoma multiforme (GBM).

Temozolomide Should be Considered for Recurrent Ependymoma

Temozolomide Should be Considered for Recurrent Ependymoma

By

Temozolomide should be considered as a possible first-line treatment for adults with intracranial ependymoma after failure of surgery and radiotherapy.

Bevacizumab May Add Survival Benefit for Wild-type Proneural Glioblastoma

Bevacizumab May Add Survival Benefit for Wild-type Proneural Glioblastoma

By

A retrospective analysis showed that first-line bevacizumab treatment may provide overall survival in glioblastoma.

Proton Therapy Well-Tolerated for Low-Grade Gliomas

Proton Therapy Well-Tolerated for Low-Grade Gliomas

Patients with low-grade glioma were found to tolerate proton radiation therapy without difficultly.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs